ReutersFDA staff question efficacy of Vertex experimental CF drug in combinationReutersFDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease. Vertex is ...FDA questions benefit of cystic fibrosis drug from VertexDaily MailFDA questions benefits of new Vertex cystic fibrosis treatmentBoston Globe (subscription)all 3 news articles »
FDA staff question efficacy of Vertex experimental CF drug in combination
Rating: 4.5
Diposkan Oleh: Unknown
